The Global Bromhexine Tablet market is projected to grow from USD 875.5 million in 2023 to USD 1,131.7 million by 2032, with a CAGR of 3.7% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory disorders and increasing demand for expectorants. Key players include Sanofi, Teva, and Boehringer Ingelheim, with market segmentation covering applications, types, and distribution channels across various regions.
India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
